Literature DB >> 17761930

Retention of low-density lipoprotein in atherosclerotic lesions of the mouse: evidence for a role of lipoprotein lipase.

Maria Gustafsson1, Malin Levin, Kristina Skålén, Jeanna Perman, Vincent Fridén, Pernilla Jirholt, Sven-Olof Olofsson, Sergio Fazio, MacRae F Linton, Clay F Semenkovich, Gunilla Olivecrona, Jan Borén.   

Abstract

Direct binding of apolipoprotein (apo)B-containing lipoproteins to proteoglycans is the initiating event in atherosclerosis, but the processes involved at later stages of development are unclear. Here, we investigated the importance of the apoB-proteoglycan interaction in the development of atherosclerosis over time and investigated the role of lipoprotein lipase (LPL) to facilitate low-density lipoprotein (LDL) retention at later stages of development. Atherosclerosis was analyzed in apoB transgenic mice expressing LDL with normal (control LDL) or reduced proteoglycan-binding (RK3359-3369SA LDL) activity after an atherogenic diet for 0 to 40 weeks. The initiation of atherosclerosis was delayed in mice expressing RK3359-3369SA LDL, but they eventually developed the same level of atherosclerosis as mice expressing control LDL. Retention studies in vivo showed that although higher levels of 131I-tyramine cellobiose-labeled control LDL (131I-TC-LDL) were retained in nonatherosclerotic aortae compared with RK3359-3369SA 131I-TC-LDL, the retention was significantly higher and there was no difference between the groups in atherosclerotic aortae. Lower levels of control 125I-TC-LDL and RK3359-3369SA 125I-TC-LDL were retained in atherosclerotic aortae from ldlr-/- mice transplanted with lpl-/- compared with lpl+/+ bone marrow. Uptake of control LDL or RK3359-3369SA LDL into macrophages with specific expression of human catalytically active or inactive LPL was increased compared with control macrophages. Furthermore, transgenic mice expressing catalytically active or inactive LPL developed the same extent of atherosclerosis. Thus, retention of LDL in the artery wall is initiated by direct LDL-proteoglycan binding but shifts to indirect binding with bridging molecules such as LPL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17761930     DOI: 10.1161/CIRCRESAHA.107.149666

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  32 in total

1.  Mechanistic roles of lipoprotein lipase and sphingomyelinase in low density lipoprotein aggregation.

Authors:  Michael J Walters; Steven P Wrenn
Journal:  J Colloid Interface Sci       Date:  2011-07-28       Impact factor: 8.128

2.  Serglycin protects against high fat diet-induced increase in serum LDL in mice.

Authors:  Astri J Meen; Christian A Drevon; Gunnar Pejler; Trond G Jenssen; Ole Kristoffer Olstad; Magnus Åbrink; Svein O Kolset
Journal:  Glycoconj J       Date:  2015-09-21       Impact factor: 2.916

3.  Elevated circulating TGF-β is not the cause of increased atherosclerosis development in biglycan deficient mice.

Authors:  Joel C Thompson; Patricia G Wilson; Alex P Wyllie; Adrian K Wyllie; Lisa R Tannock
Journal:  Atherosclerosis       Date:  2017-11-10       Impact factor: 5.162

4.  The VLDL receptor promotes lipotoxicity and increases mortality in mice following an acute myocardial infarction.

Authors:  Jeanna C Perman; Pontus Boström; Malin Lindbom; Ulf Lidberg; Marcus StÅhlman; Daniel Hägg; Henrik Lindskog; Margareta Scharin Täng; Elmir Omerovic; Lillemor Mattsson Hultén; Anders Jeppsson; Petur Petursson; Johan Herlitz; Gunilla Olivecrona; Dudley K Strickland; Kim Ekroos; Sven-Olof Olofsson; Jan Borén
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 5.  The small leucine-rich repeat proteoglycans in tissue repair and atherosclerosis.

Authors:  A Hultgårdh-Nilsson; J Borén; S Chakravarti
Journal:  J Intern Med       Date:  2015-11       Impact factor: 8.989

6.  Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation.

Authors:  Martine Bot; Ilze Bot; Rubén Lopez-Vales; Chris H A van de Lest; Jean Sébastien Saulnier-Blache; J Bernd Helms; Samuel David; Theo J C van Berkel; Erik A L Biessen
Journal:  Am J Pathol       Date:  2010-04-29       Impact factor: 4.307

7.  Acid sphingomyelinase promotes lipoprotein retention within early atheromata and accelerates lesion progression.

Authors:  Cecilia M Devlin; Andrew R Leventhal; George Kuriakose; Edward H Schuchman; Kevin Jon Williams; Ira Tabas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

8.  In vitro interactions of extracellular histones with LDL suggest a potential pro-atherogenic role.

Authors:  Alan D Pemberton; Jeremy K Brown
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

9.  Lipoprotein Lipase Deficiency Impairs Bone Marrow Myelopoiesis and Reduces Circulating Monocyte Levels.

Authors:  Chuchun L Chang; Itsaso Garcia-Arcos; Rakel Nyrén; Gunilla Olivecrona; Ji Young Kim; Yunying Hu; Rishi R Agrawal; Andrew J Murphy; Ira J Goldberg; Richard J Deckelbaum
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-01-25       Impact factor: 8.311

10.  A murine model of obesity with accelerated atherosclerosis.

Authors:  Victoria L King; Nicholas W Hatch; Huei-Wei Chan; Marcielle C de Beer; Frederick C de Beer; Lisa R Tannock
Journal:  Obesity (Silver Spring)       Date:  2009-06-04       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.